bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Update

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 271,400 shares, a decrease of 39.4% from the October 15th total of 447,500 shares. Approximately 3.7% of the company’s stock are sold short. Based on an average daily trading volume, of 115,100 shares, the days-to-cover ratio is presently 2.4 days.

bioAffinity Technologies Stock Performance

Shares of BIAF stock opened at $1.29 on Thursday. bioAffinity Technologies has a fifty-two week low of $1.25 and a fifty-two week high of $3.62. The stock’s 50-day moving average is $1.67 and its two-hundred day moving average is $1.97. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.15 and a quick ratio of 1.14. The firm has a market cap of $17.32 million, a P/E ratio of -1.40 and a beta of 3.10.

bioAffinity Technologies (NASDAQ:BIAF) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.19) EPS for the quarter. The firm had revenue of $2.40 million during the quarter. bioAffinity Technologies had a negative return on equity of 172.06% and a negative net margin of 120.76%.

Institutional Trading of bioAffinity Technologies

A hedge fund recently bought a new stake in bioAffinity Technologies stock. Ground Swell Capital LLC acquired a new stake in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 22,864 shares of the company’s stock, valued at approximately $49,000. Ground Swell Capital LLC owned about 0.20% of bioAffinity Technologies as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 1.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Maxim Group assumed coverage on shares of bioAffinity Technologies in a research note on Tuesday, July 23rd. They set a “buy” rating and a $6.00 target price for the company.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.